Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Benjamin Guy Bitler

TitleAsst Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-OB/GYN BRS

    Collapse Research 
    Collapse research activities and funding
    K99CA194318     (BITLER, BENJAMIN G)Sep 1, 2015 - Aug 31, 2017
    NIH/NCI
    Targeting Wnt signaling to overcome PARP inhibitor resistance in ovarian cancer
    Role: Principal Investigator
    R00CA194318     (BITLER, BENJAMIN G)Jan 1, 2017 - Dec 31, 2019
    NIH/NCI
    Targeting Wnt signaling to overcome PARP inhibitor resistance in ovarian cancer
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Breed C, Hicks DA, Webb PG, Galimanis CE, Bitler BG, Behbakht K, Baumgartner HK. Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel. Mol Cancer Res. 2019 03; 17(3):741-750. PMID: 30606772.
      View in: PubMed
    2. Watson ZL, Bitler BG. Type I Protein Arginine Methyltransferases Overexpression Promotes Transformation and Potentiates Her2/Neu-Driven Tumorigenesis. Cancer Res. 2019 01 01; 79(1):3-4. PMID: 30602621.
      View in: PubMed
    3. Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Post MD, Berning AA, Spillman MA, Behbakht K, Bitler BG. CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer. Oncogenesis. 2018 Nov 26; 7(11):92. PMID: 30478317.
      View in: PubMed
    4. Gordon MA, Babbs B, Cochrane DR, Bitler BG, Richer JK. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Mol Carcinog. 2019 Feb; 58(2):196-205. PMID: 30294913.
      View in: PubMed
    5. Wu S, Fatkhutdinov N, Fukumoto T, Bitler BG, Park PH, Kossenkov AV, Trizzino M, Tang HY, Zhang L, Gardini A, Speicher DW, Zhang R. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells. Nat Commun. 2018 10 08; 9(1):4116. PMID: 30297712.
      View in: PubMed
    6. Singha B, Harper SL, Goldman AR, Bitler BG, Aird KM, Borowsky ME, Cadungog MG, Liu Q, Zhang R, Jean S, Drapkin R, Speicher DW. CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. Sci Rep. 2018 Oct 03; 8(1):14725. PMID: 30282979.
      View in: PubMed
    7. Fukumoto T, Zhang R, Bitler BG. Epigenetic inhibitors for the precision treatment of ARID1A-mutant ovarian cancers: what are the next steps? Expert Rev Precis Med Drug Dev. 2018; 3(4):233-236. PMID: 30525111.
      View in: PubMed
    8. Fukumoto T, Park PH, Wu S, Fatkhutdinov N, Karakashev S, Nacarelli T, Kossenkov AV, Speicher DW, Jean S, Zhang L, Wang TL, Shih IM, Conejo-Garcia JR, Bitler BG, Zhang R. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep. 2018 03 27; 22(13):3393-3400. PMID: 29590609.
      View in: PubMed
    9. Karakashev S, Zhu H, Wu S, Yokoyama Y, Bitler BG, Park PH, Lee JH, Kossenkov AV, Gaonkar KS, Yan H, Drapkin R, Conejo-Garcia JR, Speicher DW, Ordog T, Zhang R. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nat Commun. 2018 02 12; 9(1):631. PMID: 29434212.
      View in: PubMed
    10. Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Cell Rep. 2017 Dec 19; 21(12):3398-3405. PMID: 29262321.
      View in: PubMed
    11. Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecol Oncol. 2017 12; 147(3):695-704. PMID: 29037806.
      View in: PubMed
    12. Bitler BG, Wu S, Park PH, Hai Y, Aird KM, Wang Y, Zhai Y, Kossenkov AV, Vara-Ailor A, Rauscher FJ, Zou W, Speicher DW, Huntsman DG, Conejo-Garcia JR, Cho KR, Christianson DW, Zhang R. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell Biol. 2017 08; 19(8):962-973. PMID: 28737768.
      View in: PubMed
    13. Baumgartner HK, Rudolph MC, Ramanathan P, Burns V, Webb P, Bitler BG, Stein T, Kobayashi K, Neville MC. Developmental Expression of Claudins in the Mammary Gland. J Mammary Gland Biol Neoplasia. 2017 06; 22(2):141-157. PMID: 28455726.
      View in: PubMed
    14. Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG, Zhang R. BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Res. 2016 11 01; 76(21):6320-6330. PMID: 27803105.
      View in: PubMed
    15. Aird KM, Iwasaki O, Kossenkov AV, Tanizawa H, Fatkhutdinov N, Bitler BG, Le L, Alicea G, Yang TL, Johnson FB, Noma KI, Zhang R. HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci. J Cell Biol. 2016 Nov 07; 215(3):325-334. PMID: 27799366.
      View in: PubMed
    16. Goldman AR, Bitler BG, Schug Z, Conejo-Garcia JR, Zhang R, Speicher DW. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level. Mol Cell Proteomics. 2016 11; 15(11):3348-3360. PMID: 27654507.
      View in: PubMed
    17. Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, Yokoyama Y, Kossenkov AV, Bradner JE, Conejo-Garcia JR, Zhang R. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Rep. 2016 09 13; 16(11):2829-2837. PMID: 27626654.
      View in: PubMed
    18. Wu S, Zhang R, Bitler BG. Arid1a controls tissue regeneration. Stem Cell Investig. 2016; 3:35. PMID: 27582418.
      View in: PubMed
    19. Zhu H, Ren S, Bitler BG, Aird KM, Tu Z, Skordalakes E, Zhu Y, Yan J, Sun Y, Zhang R. SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase. Cell Rep. 2015 Nov 10; 13(6):1183-1193. PMID: 26527005.
      View in: PubMed
    20. Bitler BG, Fatkhutdinov N, Zhang R. Potential therapeutic targets in ARID1A-mutated cancers. Expert Opin Ther Targets. 2015; 19(11):1419-22. PMID: 26125128.
      View in: PubMed
    21. Bitler BG, Aird KM, Zhang R. Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations. Mol Cell Oncol. 2016 Jan; 3(1):e1032476. PMID: 27308548.
      View in: PubMed
    22. Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih IeM, Conejo-Garcia JR, Speicher DW, Zhang R. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med. 2015 Mar; 21(3):231-8. PMID: 25686104.
      View in: PubMed
    23. Bitler BG, Fink LS, Wei Z, Peterson JR, Zhang R. A high-content screening assay for small-molecule modulators of oncogene-induced senescence. J Biomol Screen. 2013 Oct; 18(9):1054-61. PMID: 23733845.
      View in: PubMed
    24. Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M, Zhang R. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep. 2013 Apr 25; 3(4):1252-65. PMID: 23562156.
      View in: PubMed
    25. Garipov A, Li H, Bitler BG, Thapa RJ, Balachandran S, Zhang R. NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells. Mol Cancer Res. 2013 Apr; 11(4):360-9. PMID: 23360797.
      View in: PubMed
    26. Horm TM, Bitler BG, Broka DM, Louderbough JM, Schroeder JA. MUC1 drives c-Met-dependent migration and scattering. Mol Cancer Res. 2012 Dec; 10(12):1544-54. PMID: 23193156.
      View in: PubMed
    27. Li H, Bitler BG, Vathipadiekal V, Maradeo ME, Slifker M, Creasy CL, Tummino PJ, Cairns P, Birrer MJ, Zhang R. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila). 2012 Mar; 5(3):484-91. PMID: 22144423.
      View in: PubMed
    28. Tu Z, Aird KM, Bitler BG, Nicodemus JP, Beeharry N, Xia B, Yen TJ, Zhang R. Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence. Dev Cell. 2011 Dec 13; 21(6):1077-91. PMID: 22137763.
      View in: PubMed
    29. Bitler BG, Nicodemus JP, Li H, Cai Q, Wu H, Hua X, Li T, Birrer MJ, Godwin AK, Cairns P, Zhang R. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res. 2011 Oct 01; 71(19):6184-94. PMID: 21816908.
      View in: PubMed
    30. Dang H, Klokk TI, Schaheen B, McLaughlin BM, Thomas AJ, Durns TA, Bitler BG, Sandvig K, Fares H. Derlin-dependent retrograde transport from endosomes to the Golgi apparatus. Traffic. 2011 Oct; 12(10):1417-31. PMID: 21722281.
      View in: PubMed
    31. Bitler BG, Schroeder JA. Anti-cancer therapies that utilize cell penetrating peptides. Recent Pat Anticancer Drug Discov. 2010 Jun; 5(2):99-108. PMID: 19961434.
      View in: PubMed
    32. Bitler BG, Goverdhan A, Schroeder JA. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci. 2010 May 15; 123(Pt 10):1716-23. PMID: 20406885.
      View in: PubMed
    33. Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A, Schroeder JA. Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res. 2009 Jan 01; 15(1):100-9. PMID: 19118037.
      View in: PubMed
    34. Pfeiler E, Bitler BG, Castrezana S, Matzkin LM, Markow TA. Genetic diversification and demographic history of the cactophilic pseudoscorpion Dinocheirus arizonensis from the Sonoran Desert. Mol Phylogenet Evol. 2009 Jul; 52(1):133-41. PMID: 19166949.
      View in: PubMed
    35. Pochampalli MR, Bitler BG, Schroeder JA. Transforming growth factor alpha dependent cancer progression is modulated by Muc1. Cancer Res. 2007 Jul 15; 67(14):6591-8. PMID: 17638868.
      View in: PubMed
    36. Matzkin LM, Watts TD, Bitler BG, Machado CA, Markow TA. Functional genomics of cactus host shifts in Drosophila mojavensis. Mol Ecol. 2006 Dec; 15(14):4635-43. PMID: 17107489.
      View in: PubMed
    37. Pfeiler E, Bitler BG, Ramsey JM, Palacios-Cardiel C, Markow TA. Genetic variation, population structure, and phylogenetic relationships of Triatoma rubida and T. recurva (Hemiptera: Reduviidae: Triatominae) from the Sonoran Desert, insect vectors of the Chagas' disease parasite Trypanosoma cruzi. Mol Phylogenet Evol. 2006 Oct; 41(1):209-21. PMID: 16934496.
      View in: PubMed
    38. BITLER B, McELROY WD. The preparation and properties of crystalline firefly luciferin. Arch Biochem Biophys. 1957 Dec; 72(2):358-68. PMID: 13479120.
      View in: PubMed
    Bitler's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (224) concept(s)
    _
    Co-Authors Expand Description
    See all (6) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2019 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)